Evolving or immutable - phase I solid tumor trials in the era of precision oncology [0.03%]
精准肿瘤学时代的I期实体瘤试验：演变或恒定不变
Shannon S Stockton,G Dan Ayers,Cody Lee et al.
Shannon S Stockton et al.
In the era of precision oncology (PO), systemic therapies for patients (pts) with solid tumors have shifted from chemotherapy (CT) to targeted therapy (TT) and immunotherapy (IO). This systematic survey describes features of trials enrollin...
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial [0.03%]
Correction to：CXCR2拮抗剂纳伐利单抗联合派姆单抗治疗选择性晚期实体瘤Ⅱ期随机试验
Andrew J Armstrong,Ravit Geva,Hyun Cheol Chung et al.
Andrew J Armstrong et al.
Published Erratum
Investigational new drugs. 2024 Jun;42(3):340-341. DOI:10.1007/s10637-024-01444-0 2024
In vitro results with minimal blood toxicity of a combretastatin A4 analogue [0.03%]
一种长春瑞滨类似物的体外实验结果表明其最小血液毒性
Camila Chagas,Jaqueline Vital Mansano,Emerson Barbosa da Silva et al.
Camila Chagas et al.
Cancer is a disease caused by uncontrolled cell growth that is responsible for several deaths worldwide. Breast cancer is the most common type of cancer among women and is the leading cause of death. Chemotherapy is the most commonly used t...
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer [0.03%]
重组人端粒酶抑制剂恩度持续静滴联合铂类双药化疗治疗晚期非小细胞肺癌的疗效及安全性分析
Xinyi Liu,Zihan Guo,Lin Su et al.
Xinyi Liu et al.
Background: Platinum-based doublet chemotherapy is commonly used in the treatment of non-small cell lung cancer (NSCLC). A growing body of evidence indicates that incorporating antiangiogenic agents into platinum-based ch...
Multicenter Study
Investigational new drugs. 2024 Jun;42(3):309-317. DOI:10.1007/s10637-024-01439-x 2024
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance [0.03%]
MET选择性酪氨酸激酶抑制剂的毒性模式：真实世界药物警戒证据
Wenjie Li,Wei Wang
Wenjie Li
MET exon 14 skipping alterations and MET amplifications are recognized as oncogenic and targetable genetic changes in cancer patients. The treatment of MET-selective tyrosine kinase inhibitors (TKIs) in this specific population has shown en...
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia [0.03%]
关于布鲁顿酪氨酸激酶抑制剂治疗套细胞淋巴瘤的中国真实世界研究：BLINCELL研究
Huifen Zhou,Xiaoxia Wu,Zhen Yang et al.
Huifen Zhou et al.
Blinatumomab is efficacious in patients with B-cell acute lymphoblastic leukemia (B-ALL), yet limited real-world data exists in this context. This retrospective study provided real-world data on the treatment pattern, effectiveness, and saf...
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects [0.03%]
食物对sutemtinib马来酸胶囊（不可逆的EGFR酪氨酸激酶抑制剂）在中国健康受试者中药代动力学影响的研究
Bei Cao,Tingting Ma,Yuqiang Zhang et al.
Bei Cao et al.
Sutetinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and showed favorable efficacy and safety in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring nondrug-resistant rare ...
Randomized Controlled Trial
Investigational new drugs. 2024 Jun;42(3):289-298. DOI:10.1007/s10637-024-01436-0 2024
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells [0.03%]
人胎盘间充质干细胞分泌组通过降低乳腺癌细胞FAK活性和减少细胞粘附蛋白表达来抑制癌细胞迁移能力
Fatemeh Safari,Setareh Bararpour,Fatemeh Omidi Chomachaei
Fatemeh Safari
Breast cancer is a leading cause of death in women worldwide. Cancer therapy based on stem cells is considered as a novel and promising platform. In the present study, we explore the therapeutic effects of human amniotic mesenchymal stromal...
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer [0.03%]
早期降低奥希替尼剂量对一线治疗EGFR突变非小细胞肺癌疗效的影响
Tomoki Hori,Kazuhiro Yamamoto,Takefumi Ito et al.
Tomoki Hori et al.
Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, early dose reduction is often required due to adverse events (AEs). This study aime...
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer [0.03%]
关于epacadostat、派姆单抗和化疗联合治疗先前未接受过治疗的晚期非小细胞肺癌患者的I期试验(KEYNOTE-434) B部分
Noboru Yamamoto,Miyako Satouchi,Toshihiko Doi et al.
Noboru Yamamoto et al.
Background: Pembrolizumab plus epacadostat (indoleamine 2,3-dioxygenase-1 inhibitor) was well tolerated in Japanese patients with advanced solid tumors in part A of the nonrandomized, open-label, phase 1 KEYNOTE-434 study...